Tempest Therapeutics Inc - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
TPST Nasdaq 8731 https://www.tempesttx.com/

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tempest Therapeutics Inc

Tempest to Present at the Jefferies Global Healthcare Conference - May 31st, 2023 8:05 pm
Tempest to Present Phase 1 Monotherapy and Combination Data at ASCO for TPST-1495 in Patients with Advanced Cancers - May 25th, 2023 9:00 pm
Tempest Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 19th, 2023 8:05 pm
Tempest Reports First Quarter 2023 Financial Results and Provides Business Update - May 10th, 2023 8:15 pm
Tempest Announces Positive Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma - Apr 28th, 2023 12:00 pm
Tempest to Report Early Results from Global Randomized Phase 1b/2 Combination Study of TPST-1120 in First-Line Hepatocellular Carcinoma - Apr 27th, 2023 8:58 pm
Tempest Announces TPST-1495 Poster Presentation at the 2023 ASCO Annual Meeting - Apr 26th, 2023 10:41 pm
Tempest Announces New Translational and Preclinical Data Presented at the 2023 AACR Annual Meeting - Apr 17th, 2023 1:00 pm
Tempest Reports Year End 2022 Financial Results and Provides Business Update - Mar 22nd, 2023 9:26 pm
Tempest to Present Biomarker Data for TPST-1120 at the Society for Immunotherapy of Cancer (SITC) 2023 Spring Scientific Meeting - Mar 15th, 2023 8:05 pm
Tempest to Present New Translational and Preclinical Data at the 2023 AACR Annual Meeting - Mar 14th, 2023 8:30 pm
Tempest to Present at the Piper Sandler 34th Annual Healthcare Conference - Nov 22nd, 2022 9:05 pm
Tempest Presents Data Showing TPST-1120-Induced Pharmacodynamic Changes Consistent with Clinical Benefit Observed in Patients with Cancer - Nov 10th, 2022 2:00 pm
Tempest Reports Third Quarter 2022 Financial Results and Provides Business Update - Nov 8th, 2022 1:00 pm
Tempest Announces Data Presentations, including a Late-Breaking Presentation on TPST-1120, at the SITC Annual Meeting - Nov 2nd, 2022 12:00 pm
Tempest to Present at Emerging Technologies for IO Targeting and Discovery Summit - Oct 6th, 2022 12:00 pm
Tempest to Present at the H.C. Wainwright 24th Annual Global Investment Conference - Sep 7th, 2022 12:00 pm
Tempest Reports Second Quarter 2022 Financial Results and Provides Business Update - Aug 15th, 2022 12:00 pm
Tempest to Participate in Panel Discussion at 2022 William Blair Biotech Focus Conference - Jul 7th, 2022 12:00 pm
Tempest Provides ASCO KOL Feedback on TPST-1120 Clinical Results and Updated Financial Guidance - Jun 9th, 2022 12:00 pm